Sanofi's Amlitelimab Shows Promising Results in Phase 3 Atopic Dermatitis Studies

Sanofi presented positive results from phase 3 studies of amlitelimab, a monoclonal antibody targeting OX40-ligand, at the American Academy of Dermatology meeting. The studies, COAST 1, COAST 2, and SHORE, assessed amlitelimab's efficacy in moderate-to-severe atopic dermatitis.

Amlitelimab demonstrated increasing efficacy over 24 weeks at dosing intervals of every four or twelve weeks, showing improvements in skin clearance and disease severity. The SHORE study highlighted its effectiveness in combination with topical treatments.

In terms of safety, amlitelimab was generally well-tolerated. Common treatment-emergent adverse events included nasopharyngitis and dermatitis atopic, with low malignancy rates reported.

These findings suggest amlitelimab's potential to address unmet needs in atopic dermatitis treatment, with anticipated results from the ESTUARY extension study expected later in 2026. Amlitelimab remains in clinical development, pending regulatory evaluation.